Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application.
From the perspective of a pilot clinical gene therapy trial for Wiskott-Aldrich syndrome (WAS), we implemented a process to produce a lentiviral vector under good manufacturing practices (GMP). The process is based on the transient transfection of 293T cells in Cell Factory stacks, scaled up to harvest 50 liters of viral stock per batch, followed by purification of the vesicular stomatitis virus glycoprotein-pseudotyped particles through several membrane-based and chromatographic steps. The process leads to a 200-fold volume concentration and an approximately 3-log reduction in protein and DNA contaminants. An average yield of 13% of infectious particles was obtained in six full-scale preparations. The final product contained low levels of contaminants such as simian virus 40 large T antigen or E1A sequences originating from producer cells. Titers as high as 2 × 10(9) infectious particles per milliliter were obtained, generating up to 6 × 10(11) infectious particles per batch. The purified WAS vector was biologically active, efficiently expressing the genetic insert in WAS protein-deficient B cell lines and transducing CD34(+) cells. The vector introduced 0.3-1 vector copy per cell on average in CD34(+) cells when used at the concentration of 10(8) infectious particles per milliliter, which is comparable to preclinical preparations. There was no evidence of cellular toxicity. These results show the implementation of large-scale GMP production, purification, and control of advanced HIV-1-derived lentiviral technology. Results obtained with the WAS vector provide the initial manufacturing and quality control benchmarking that should be helpful to further development and clinical applications.
Généthon, F-91002 Evry, France. omerten@genethon.fr
Otto-Wilhelm
OW
Merten
Sabine
S
Charrier
Nicolas
N
Laroudie
Sylvain
S
Fauchille
Céline
C
Dugué
Christine
C
Jenny
Muriel
M
Audit
Maria-Antonietta
MA
Zanta-Boussif
Hélène
H
Chautard
Marina
M
Radrizzani
Giuliana
G
Vallanti
Luigi
L
Naldini
Patricia
P
Noguiez-Hellin
Anne
A
Galy
D018929:Cell Culture Techniques; D002460:Cell Line; D004340:Drug Contamination / Q000331:legislation & jurisprudence / Q000517:prevention & control; D005786:Gene Expression Regulation; D023061:Gene Order; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000096:biosynthesis* / Q000235:genetics* / Q000502:physiology; D057809:HEK293 Cells; D006412:Hematopoietic Stem Cells / Q000378:metabolism; D006801:Humans; D007218:Industrial Microbiology / Q000379:methods*; D016086:Lentivirus / Q000235:genetics* / Q000502:physiology; D010957:Plasmids / Q000235:genetics; D011533:Proviruses / Q000235:genetics; D011786:Quality Control; D014161:Transduction, Genetic; D019076:Transgenes / Q000235:genetics; D014923:Wiskott-Aldrich Syndrome / Q000628:therapy